NanoVelos
Verified IntelNANOVELOS - Drug Release Control Technology offered by NanoVelos demonstrates its power by transforming generics to super-generics via an innovative delivery system: they exhibit dramatically improved tumor targeting, thereby enhancing therapy efficacy while minimizing adverse effects on healthy tissues. Nanovelos offers also an adaptation of its proprietary drug delivery system for your anticancer drug. We can conjugate highly potent drugs that struggle to enter preclinical or clinical trials due to the intolerable toxicity or fast clearance.
NANOVELOS - Drug Release Control Technology offered by NanoVelos demonstrates its power by transforming generics to super-generics via an innovative delivery system: they exhibit dramatically improved tumor targeting, thereby enhancing therapy efficacy while minimizing adverse effects on healthy tissues. Nanovelos offers also an adaptation of its proprietary drug delivery system for your anticancer drug. We can conjugate highly potent drugs that struggle to enter preclinical or clinical trials due to the intolerable toxicity or fast clearance.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Privately Held
- Founded
- 2013
- Employee Bracket
- 1-10
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- Rakowiecka36 Warsaw
- City
- Warsaw
- Region / State
- Mazowieckie
- Postal Code
- 05-532
- Country
- Poland
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for NanoVelos.